Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .	Chemotherapy; Metastatic Gastric Adenocarcinoma; Second Line	Recruiting	Phase 1 / Phase 2	2026-04-09		NCT05927857

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Chang Gung Memorial Hospital	214
China Medical University Hospital	112
Kaohsiung Medical University Chung-Ho Memorial Hospital	56
National Cheng-Kung University Hospital	83
National Health Research Institutes, Taiwan	52
Taipei Veterans General Hospital, Taiwan	80

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Taipei Veterans General Hospital	Taipei	Taiwan	3